Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

#Opdivo, the first and only subcutaneously administered PD-1 inhibitor, is endorsed by FDA. "For patients receiving OPDIVO 240 mg every 2 weeks, the list price is $7,635 per infusion, as of 1st ...

Correspondence to Professor Susumu Kusunoki, Department of Neurology, Kindai University Faculty of Medicine, 377+2 Ohno+Higashi, Osaka+Sayama, Osaka, 589+8511 Japan; kusunoki-tky{at}umin.ac.jp ...